MEDICINE BEYOND BORDERS

Providing Manufacturing Breakthroughs That Lower the Cost of Life Saving Drugs

MEDICINE BEYOND BORDERS

Providing Manufacturing Breakthroughs That Lower the Cost of Life Saving Drugs

Medicine Beyond Borders

Providing the World's Disease Epicenters with Millions of Prescriptions for NCD's and Infectious Diseases.

  • Malaria

  • Cancer

  • Orphan Drugs

  • Acute Respiratory Infections

  • GI Infections

  • COVID 19

  • Dengue Fever
  • AIDS and other STD's

  • Tuberculosis

About Dr. Ashleys

Dr. Ashleys is a historically profitable pharmaceutical company dedicated to the development and manufacturing of specialized and complex active pharmaceutical ingredients (APIs) and orphan drugs. The company's expertise spans across various critical health areas, including malaria, cancer, gastrointestinal disorders, acute respiratory infections, COVID-19, dengue fever, tuberculosis, and other infectious diseases.

Under the visionary leadership of Dr. Kanans Visvanants FRSC (Dr. Kanans), a second-generation pharmaceutical and chemical engineer, the company revolutionized the industry by significantly reducing the cost of manufacturing generic and patented drugs. With 13 manufacturing patents, the company provides over 300 million annual medical doses to the world's disease epicenters, addressing both non-communicable diseases (NCDs) and infectious diseases.

Oncology (Cancer)

Hormonal Therapies

Antibiotics (Bacterial Infections)

Cardiovascular Diseases

Neurological Disorders

Antiviral Treatments

0
Patents
0+
Million Annual Doses
0
Products
0+
Distributors
0
Patents
0+
Million Annual Doses
0
Products
0+
Distributors

Why We Are Important

Delivering life-saving drugs to hard-to-reach places

  • Malaria - Our patented Malaria drug is the industry's lowest cost drug focusing on the market for 263 million annual cases worldwide. The African region represents 94% of all Malaria cases. Dr. Ashleys is one of the largest distributors of Malaria drugs to Africa.

    Notably, the company is the market leader in Antimalarial APIs and ranks as the world's third-largest contract manufacturer of Quinine salts.

  • Anti-Cancer Drugs - Our low-cost pharmaceutical manufacturing of anti-cancer drugs is being received as a cutting-edge break through. Our anti-cancer drug has been approved in Malaysia with pending initial distribution approval throughout South East Asia and beyond. Our anti-cancer drugs are projected to represent 50% of Dr. Ashelys’ manufacturing and distribution base.
  • Orphan Drugs for Rare Diseases - Dr. Ashleys has taken the profitable leadership role in the underserved and limited production market of Orphan Drugs for rare diseases. Biospace.com reported that the Orphan Drug Market is currently valued at around $170 - $215 billion with projections to reach over $500 billion by 2032, demonstrating significant growth driven by increasing awareness of rare diseases and supportive regulations for orphan drug development.

    Through Dr. Ashleys’ patented low-cost pharmaceutical manufacturing technology, we are able to process critical care medicines for rare diseases. While leading drug manufacturers are finding it difficult to profitably compete in this specialized market, Dr. Ashleys’ low cost manufacturing technologies has revitalized the unmet critical care for the Orphan Drug manufacturing market.

Where We Are Going

Our team of pharmaceutical engineers and scientists are committed to building on our success through continual research of profitable technology manufacturing breakthroughs that lower the cost and distribution of generic and patented drugs.

Active Pharmaceutical Ingredients

The Active Pharmaceutical Ingredients (APIs) business is a cornerstone of Dr. Ashleys pharmaceutical operations.

orphan Drugs

Taking a leadership role in the underserved and the limited production market of orphan drugs for rare diseases.

CRAMS

Contract Research & Manufacturing Services. Our Contract manufacturing units have a host of sophisticated, new-age technologies that are focused on product precision, quality and efficient delivery.

Dr Kanans Visvanats FRSC / Dr. Kanans

Recipient of the Albert Schweitzer Award in Medicine by The Albert Schweitzer Foundation

Growing up in India as a son of a successful pharmaceutical manufacturer, Dr. Kanans was destined to make his mark beyond his country to become a global manufacturer. After obtaining a degree in Chemical Engineering, Dr. Kanans began to redefine the industry’s manufacturing processes for generic and patented drugs to reduce manufacturing costs and delivery systems. His first breakthrough was lowering the manufacturing cost for the treatment of Malaria. Because of his patented manufacturing, he is responsible for the low-cost distribution of millions of doses throughout third world countries and other critical Malaria hot spots.